Monoclonal Antibodies Blocking AGR2 and C4.4A Interaction
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Current anti-cancer therapies lack effective targets for inhibiting the aggressive growth and metastasis of cancer cells, particularly in pancreatic ductal adenocarcinoma, where AGR2 and its receptor C4.4A play a crucial role in promoting tumor cell aggressiveness and chemoresistance.
Innovation Solution
Development of monoclonal blocking antibodies specifically binding to AGR2 and C4.4A, which disrupt the AGR2/C4.4A autocrine signaling loop, thereby inhibiting tumor cell migration and resistance to apoptosis.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Reliability
If AGR2 and its receptor C4.4A are targeted for therapeutic intervention, then tumor growth and metastasis are reduced, but the complexity of identifying and validating the receptor target increases
Solution Approach 1:
The patent uses yeast two-hybrid screening as an intermediary method to identify and validate the C4.4A receptor for AGR2. This mediator approach systematically bridges the gap between the known oncogenic role of AGR2 and the need to identify its specific cellular receptor, thereby reducing the complexity of direct target validation in mammalian systems.
Solution Approach 2:
The patent performs preliminary validation of the AGR2-C4.4A interaction in yeast systems before applying therapeutic interventions in mammalian cancer models. This preliminary action establishes the receptor-ligand relationship in a controlled environment, reducing the complexity of subsequent therapeutic development and validation in more complex systems.
2Reliability
If monoclonal antibodies are developed to block AGR2/C4.4A interaction, then tumor cell migration and chemoresistance are inhibited, but the time and resources required for antibody development increase
Solution Approach 1:
The patent performs preliminary validation of the AGR2-C4.4A interaction in yeast systems before applying therapeutic interventions in mammalian cancer models. This preliminary action establishes the receptor-ligand relationship in a controlled environment, reducing the complexity of subsequent therapeutic development and validation in more complex systems.
Solution Approach 2:
The patent uses yeast two-hybrid screening as an intermediary method to identify and validate the C4.4A receptor for AGR2. This mediator approach systematically bridges the gap between the known oncogenic role of AGR2 and the need to identify its specific cellular receptor, thereby reducing the complexity of direct target validation in mammalian systems.
3Object-affected harmful factors
If AGR2 function is blocked to reduce tumor growth, then metastasis is reduced, but the mechanisms of AGR2 in normal protein synthesis must be considered to avoid off-target effects
Solution Approach 1:
The patent employs monoclonal antibodies that specifically target either AGR2 or C4.4A with high specificity, ensuring that the therapeutic effect is localized to the cancer cell population expressing these molecules. This local quality approach minimizes off-target effects on normal tissues by exploiting the differential expression of AGR2/C4.4A in tumor versus normal cells.
Solution Approach 2:
The patent uses yeast two-hybrid screening as an intermediary method to identify and validate the C4.4A receptor for AGR2. This mediator approach systematically bridges the gap between the known oncogenic role of AGR2 and the need to identify its specific cellular receptor, thereby reducing the complexity of direct target validation in mammalian systems.
Data Source
AI summary
Provided herein are monoclonal antibodies that recognize, bind to, and block interactions of other molecules with AGR2 and C4.4A. Also provided herein are methods of using anti-AGR2 and anti-C4.4A antibodies to treat cancer.